Infusion of soluble myelin basic protein protects long term against induction of experimental autoimmune encephalomyelitis-Reference-Cited by-同舟云学术

Infusion of soluble myelin basic protein protects long term against induction of experimental autoimmune encephalomyelitis

Published:1997-02 Issue:1 Volume:75 Page:54-64
ISSN:0818-9641
Container-title:Immunology and Cell Biology
language:en
Short-container-title:Immunol Cell Biol

Author:

Staykova Maria A¹,Simmons Rex D¹,Willenborg David O¹

Affiliation:

1. Neurosciences Research Unit, ACT National Health Sciences Centre, The Canberra Hospital; Canberra Australian Capital Territory Australia

Publisher

Wiley

Subject

Cell Biology,Immunology,Immunology and Allergy

Link

http://www.nature.com/articles/icb19979.pdf

Reference50 articles.

1. Suppressor cell control of un-responsiveness to experimental allergic encephalomyelitis;Swierkosz;J. Immunol.,1975

2. Characterization of suppressor cells involved in regulation of experimental allergic encephalomyelitis;Swierkosz;Eur. J. Immunol.,1976

3. Immunoregulation of experimental allergic encephalomyelitis: Conditions for induction of suppressor cells and analysis of mechanism;Swierkosz;J. Immunol.,1977

4. Protection against experimental allergic encephalomyelitis with peptides derived from myelin basic protein: Presence of intact encephalitogenic site is essential;Driscoll;J. Immunol.,1976

5. Amelioration of autoimmune encephalomyelitis by myelin basic protein synthetic peptide-induced anergy;Gaur;Science,1992

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Therapeutic potential of tolerance-based peptide vaccines in autoimmune diseases;International Immunopharmacology;2023-03

2. Targeting Antigen-Presenting Cells in Multiple Sclerosis Treatment;Applied Sciences;2021-09-15

3. Emerging Therapeutics for Immune Tolerance: Tolerogenic Vaccines, T cell Therapy, and IL-2 Therapy;Frontiers in Immunology;2021-03-29

4. Immune modulating peptides for the treatment and suppression of multiple sclerosis;Clinical Immunology;2012-08

5. Intravenous synthetic peptide MBP8298 delayed disease progression in an HLA Class II-defined cohort of patients with progressive multiple sclerosis: results of a 24-month double-blind placebo-controlled clinical trial and 5 years of follow-up treatment;European Journal of Neurology;2006-08